A detailed history of Two Sigma Investments, LP transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Two Sigma Investments, LP holds 28,585 shares of BCYC stock, worth $559,694. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,585
Previous 103,628 72.42%
Holding current value
$559,694
Previous $1.87 Million 62.04%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$16.75 - $26.1 $1.26 Million - $1.96 Million
-75,043 Reduced 72.42%
28,585 $711,000
Q4 2023

Feb 14, 2024

BUY
$13.29 - $22.2 $1.07 Million - $1.79 Million
80,698 Added 351.93%
103,628 $1.87 Million
Q3 2023

Nov 14, 2023

SELL
$19.9 - $26.25 $590,950 - $779,520
-29,696 Reduced 56.43%
22,930 $460,000
Q2 2023

Aug 14, 2023

SELL
$18.95 - $28.67 $2.05 Million - $3.09 Million
-107,950 Reduced 67.23%
52,626 $1.34 Million
Q1 2023

May 15, 2023

BUY
$20.02 - $31.37 $3.21 Million - $5.04 Million
160,576 New
160,576 $3.42 Million
Q3 2022

Nov 14, 2022

SELL
$17.49 - $28.44 $5.79 Million - $9.42 Million
-331,154 Reduced 87.0%
49,500 $1.15 Million
Q2 2022

Aug 15, 2022

BUY
$12.95 - $46.99 $2.63 Million - $9.55 Million
203,332 Added 114.67%
380,654 $6.39 Million
Q1 2022

May 16, 2022

BUY
$40.12 - $59.5 $1.04 Million - $1.54 Million
25,961 Added 17.15%
177,322 $7.78 Million
Q4 2021

Feb 14, 2022

BUY
$41.7 - $61.14 $2.47 Million - $3.62 Million
59,169 Added 64.18%
151,361 $9.21 Million
Q3 2021

Nov 15, 2021

BUY
$27.95 - $44.24 $2.58 Million - $4.08 Million
92,192 New
92,192 $3.83 Million
Q1 2021

May 17, 2021

SELL
$19.12 - $30.25 $390,028 - $617,069
-20,399 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$17.95 - $21.36 $366,162 - $435,722
20,399 New
20,399 $366,000

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $581M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.